Literature DB >> 18442209

Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.

Li-Ning Xu1, Xin Wang, Sheng-Quan Zou.   

Abstract

AIM: To explore the effect of histone deacetylase inhibitor, trichostatin A (TSA) on the growth of biliary tract cancer cell lines (gallbladder carcinoma cell line and cholangiocarcinoma cell line) in vivo and in vitro, and to investigate the perspective of histone deacetylase inhibitor in its clinical application.
METHODS: The survival rates of gallbladder carcinoma cell line (Mz-ChA-l cell line) and cholangiocarcinoma cell lines (QBC939, KMBC and OZ cell lines) treated with various doses of TSA were detected by methylthiazoy tetrazolium (MTT) assay. A nude mouse model of transplanted gallbladder carcinoma (Mz-ChA-l cell line) was successfully established, and changes in the growth of transplanted tumor after treated with TSA were measured.
RESULTS: TSA could inhibit the proliferation of gallbladder carcinoma cell line (Mz-ChA-l cell line) and cholangiocarcinoma cell lines (QBC939, KMBC and OZ cell lines) in a dose-dependent manner. After the nude mouse model of transplanted gallbladder carcinoma (Mz-ChA-l cell line) was successfully established, the growth of cancer was inhibited in the model after treated with TSA.
CONCLUSION: TSA can inhibit the growth of cholangiocarcinoma and gallbladder carcinoma cell lines in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18442209      PMCID: PMC2708373          DOI: 10.3748/wjg.14.2578

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

Review 1.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.

Authors:  Paola Gallinari; Stefania Di Marco; Phillip Jones; Michele Pallaoro; Christian Steinkühler
Journal:  Cell Res       Date:  2007-03       Impact factor: 25.617

Review 2.  Chemoradiotherapy in gallbladder cancer.

Authors:  Xabier de Aretxabala; Ivan Roa; Marcela Berrios; Juan Hepp; Jorge Gallardo; Andres Cordova; Juan Carlos Roa; Jorge Leon; Fernando Maluenda
Journal:  J Surg Oncol       Date:  2006-06-15       Impact factor: 3.454

3.  The genetic differences between gallbladder and bile duct cancer cell lines.

Authors:  Soichiro Saito; Mila Ghosh; Keiko Morita; Takashi Hirano; Masanao Miwa; Takeshi Todoroki
Journal:  Oncol Rep       Date:  2006-11       Impact factor: 3.906

4.  Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial.

Authors:  Gen Sugawara; Masato Nagino; Hideki Nishio; Tomoki Ebata; Kenji Takagi; Takashi Asahara; Koji Nomoto; Yuji Nimura
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

5.  Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.

Authors:  Changlin Zhou; Lihua Qiu; Yun Sun; Sarah Healey; Harold Wanebo; Nicola Kouttab; Wen Di; Bingfang Yan; Yinsheng Wan
Journal:  Int J Oncol       Date:  2006-07       Impact factor: 5.650

Review 6.  Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review.

Authors:  Rossana Berardi; Berardi Rossana; Mario Scartozzi; Scartozzi Mario; Federica Freddari; Freddari Federica; Michela Squadroni; Squadroni Michela; Alfredo Santinelli; Santinelli Alfredo; Italo Bearzi; Bearzi Italo; Guidalberto Fabris; Fabris Guidalberto; Stefano Cascinu; Cascinu Stefano
Journal:  Cancer Treat Rev       Date:  2006-06-09       Impact factor: 12.111

Review 7.  Targeting histone deacetylase in cancer therapy.

Authors:  Hsiang-Yu Lin; Chang-Shi Chen; Shuan-Pei Lin; Jing-Ru Weng; Ching-Shih Chen
Journal:  Med Res Rev       Date:  2006-07       Impact factor: 12.944

8.  Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002.

Authors:  M T Goodman; Jennifer Yamamoto
Journal:  Cancer Causes Control       Date:  2007-01-30       Impact factor: 2.506

Review 9.  Chromatin remodeling, cancer and chemotherapy.

Authors:  Pranab Dey
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

10.  Bile acid analysis in biliary tract cancer.

Authors:  Jeong Youp Park; Byung Kyu Park; Jun Sang Ko; Seungmin Bang; Si Young Song; Jae Bock Chung
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

View more
  8 in total

Review 1.  The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Authors:  Richard L Bennett; Alok Swaroop; Catalina Troche; Jonathan D Licht
Journal:  Cold Spring Harb Perspect Med       Date:  2017-06-01       Impact factor: 6.915

2.  Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.

Authors:  James L Chen; Tanios Bekaii-Saab; Daniel H Ahn; Milind Javle; Chul W Ahn; Apurva Jain; Sameh Mikhail; Anne M Noonan; Kristen Ciombor; Christina Wu; Rachna T Shroff
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

Review 3.  The significance of genetics for cholangiocarcinoma development.

Authors:  Luca Maroni; Irene Pierantonelli; Jesus M Banales; Antonio Benedetti; Marco Marzioni
Journal:  Ann Transl Med       Date:  2013-10

4.  Overexpression of histone deacetylase 2 predicts unfavorable prognosis in human gallbladder carcinoma.

Authors:  Xilin Du; Huadong Zhao; Li Zang; Nuan Song; Tao Yang; Rui Dong; Jikai Yin; Chengguo Wang; Jianguo Lu
Journal:  Pathol Oncol Res       Date:  2012-12-16       Impact factor: 3.201

5.  KAT5 silencing induces apoptosis of GBC-SD cells through p38MAPK-mediated upregulation of cleaved Casp9.

Authors:  Fei-Ling Feng; Yong Yu; Chen Liu; Bai-He Zhang; Qing-Bao Cheng; Bin Li; Wei-Feng Tan; Xiang-Ji Luo; Xiao-Qing Jiang
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

6.  TGF-β1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4.

Authors:  Huiling Wang; Caixia Li; Zhixiang Jian; Yingliang Ou; Jinrui Ou
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

7.  Sodium valproate inhibits the growth of human cholangiocarcinoma in vitro and in vivo.

Authors:  Bing Wang; Rui Yang; Yue Wu; Hongbo Li; Zouxiao Hu; Yongjun Chen; Shengquan Zou
Journal:  Gastroenterol Res Pract       Date:  2013-11-13       Impact factor: 2.260

8.  CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.

Authors:  Dawoon E Jung; Soo Been Park; Kahee Kim; Chanyang Kim; Si Young Song
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.